CV event rate by mean achieved LDL-C level with statin therapy, proven over 25 years of clinical trials1,2
Figure adapted from Raymond C, et al. Cleve Clin J Med. 2014;81:11-19.
Shows a scatterplot with best-fit line of major statin trials for secondary prevention of coronary heart disease events.
Key secondary endpoint: composite of cardiovascular death, myocardial infarction, or stroke6,7
Repatha® added to a statin reduced the risk of composite CV events by 20% in a median of 2.2 years, and the benefit improved over time.6
- Primary composite endpoint of time to CV death, MI, hospitalization for unstable angina, stroke, or coronary revascularization: HR 0.85 (95% CI, 0.79-0.92; P<0.0001)6
- Stroke=21% RRR6
- Key secondary composite endpoint of time to CV death, MI, or stroke: HR 0.80 (95% CI, 0.73-0.88; P<0.0001). ARR=2.0%6,7
- Relative risk reductions for the primary and secondary composite endpoints were driven by a reduction in the risk of MI: HR 0.73 (95% CI, 0.65-0.82), stroke: HR 0.79 (95% CI, 0.66-0.95), and coronary revascularization: HR 0.78 (95% CI, 0.71-0.86)6
Observed HR for CV death: 1.05 (95% Cl, 0.88-1.25) and hospitalizations due to unstable angina: 0.99 (95% Cl, 0.82-1.18)6
When compared to the overall study population, a greater ARR was observed in patients with a qualifying MI <2 years8
ARR of 2.0% in the overall Repatha® CV Outcomes Trial study population was evaluated at 36 months6,7
- Repatha® reduced the risk of CV death, MI, or stroke by 24% in patients with a qualifying MI <2 years ago8
- Analysis of 81% (n=22,351) of patients in Repatha® CV Outcomes Trial with MI as their qualifying event; median time from MI to enrollment in Repatha® CV Outcomes Trial was 3.3 years7
- The observed HR for CV death was 1.05 (95% CI, 0.88-1.25) from the primary analysis6
ACC/AHA=American College of Cardiology/American Heart Association; ARB=angiotensin II receptor blocker; ARR=absolute risk reduction; ASCVD=atherosclerotic cardiovascular disease; BID=twice daily; BMI=body mass index; CABG=coronary artery bypass graft; CI=confidence interval; CV=cardiovascular; CVD=cardiovascular disease; HDL-C=high-density lipoprotein cholesterol; HR=hazard ratio; IS=ischemic stroke; LDL-C=low-density lipoprotein cholesterol; MI=myocardial infarction; NSTE-ACS=non-ST-segment elevation acute coronary syndrome; NSTEMI=non-ST-elevation myocardial infarction; PCI=percutaneous coronary intervention; PCSK9=proprotein convertase subtilisin/kexin type 9; PRN=as needed; QD=once daily; RRR=relative risk reduction; TC=total cholesterol; TG=triglycerides; UA=unstable angina.
References: 1. Raymond C, Cho L, Rocco M, et al. New guidelines for reduction of blood cholesterol: Was it worth the wait? Cleve Clin J Med. 2014;81:11-19. 2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;34:1383-1389. 3. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/ AACVPR/AAPA/ABC/ ACPM/ ADA/ AGS/ APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol. J Am Coll Cardiol. 2019;73:e285-e350. 4. Li S, Peng Y, Wang X, et al. Cardiovascular events and death after myocardial infarction or ischemic stroke in an older Medicare population. Clin Cardiol. 2019;42:391-399. 5. Data on file, Amgen; 2020. 6. Repatha® (evolocumab) prescribing information, Amgen. 7. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713-1722. 8. Sabatine MS, De Ferrari GM, Giugliano RP, et al. Clinical benefit of evolocumab by severity and extent of coronary artery disease: an analysis from FOURIER. Circulation. 2018;138:756-766. 9. Yusuf S, Hawken S, Ôunpuu S, et al; on behalf of the INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-controlled study. Lancet. 2004;364:937-952. 10. Data on file, Amgen; 2017. 11. Data on file, Amgen; 2017.